Ophthalmic giant Bausch + Lomb (B+L), which is being spun-off from its parent as a pure-play eye health company, has filed to raise up to US$840 million (AU$1.2 billion) in an initial public offering (IPO). Read more
Australia’s most-trusted optometry brands revealed
Specsavers has been crowned one of Australia’s most-trusted optometry brands, as judged by Reader’s Digest Magazine’s annual consumer survey, while also being recognised in the Contact Lens Solution and Hearing Services categories. Read more
Eye disease AI screening system TGA-approved
The Therapeutic Goods Administration (TGA) has approved a new AI software system that can screen for three major eye diseases in primary care settings. Read more
EssilorLuxottica makes play for eyeglass cases and packaging business
As it took 100% control of GrandVision and offloaded 177 stores this month, EssilorLuxottica announced a leadership reshuffle for the optical retail giant, including a new CEO. Read more
Lumibird Medical unveils new Capsulo Nd:YAG laser
Lumibird Medical has launched its new Capsulo Nd:YAG laser platform, designed for efficient and accurate capsulotomy and iridotomy treatments. Read more
Nova Eye Medical officially launches next-gen iTrack Advance
ASX-listed ophthalmic technology company Nova Eye Medical expects more cataract surgeons and comprehensive ophthalmologists to uptake its glaucoma canaloplasty procedure, with the launch of its improved iTrack device in select Europe and Asia Pacific markets this week. Read more
Corporate responsibility: Upholding the common good
Corporate responsibility has been anchored in the Zeiss business mindset since its foundation. Insight examines how its historic principles are living up to its commitments to Australasian employees and the environment in 2022. Read more
Rodenstock exploits potential of standard refraction values in updated B.I.G. portfolio
Rodenstock has unveiled the latest innovations in its ophthalmic lens portfolio in Australia, featuring new B.I.G. NORM lenses that incorporate a precise AI-based biometric model of the eye using only the four standard refraction values. Read more
Glaukos commences trials for its third-generation keratoconus therapy
Glaukos has commenced a Phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Read more
Charles Hornor calls time on Specsavers career
As he calls it a day, CHARLES HORNOR recounts the moment he and Peter Larsen sent an email to Specsavers, triggering a wave of momentum that continues 16 years on.